---
title: Publications
---

# Publications

<div class="card" style="max-width:980px; margin:18px auto; padding:16px; border-radius:14px; border:1px solid rgba(0,0,0,.08); background: rgba(0,0,0,.01);">

  <p class="small" style="margin:0 0 10px; line-height:1.6;">
    <strong>Legend:</strong> <code>*</code> Corresponding author · <code>^</code> Co-first author
  </p>

  <h3 style="margin-top:18px;">2025</h3>
  <ol class="small" style="line-height:1.6;">
    <li>Tanaka S, Wilkens LR, Le Marchand L, Yang G, Yuan JM, Koh WP, Shrubsole MJ, Luu M, Pagano I, <strong>Furuya H</strong>, Rosser CJ. Developing a prediction model in a large case-control study for the early detection of bladder cancer. <em>J Transl Med.</em> 2025 Dec 5. doi: 10.1186/s12967-025-07511-1. Online ahead of print. PMID: 41351005.</li>
    <li>Levy J, Sakatani T, Murakami K, Kita Y, Kobayashi T, Win S, Manoukian S, Rosser CJ, <strong>Furuya H</strong>. Comparative analysis of CT and MRI combined with RNA sequencing for radiogenomic staging of bladder cancer. <em>Int J Mol Sci.</em> 2025 Sep 30;26(19):9570. doi: 10.3390/ijms26199570. PMID: 41096834. *Corresponding author</li>
    <li>Fujita K, Miyake M, Hashimoto M, Shimizu T, Linehan J, Gottlieb J, Pagano I, Tikhonenkov S, Luu M, Tanaka S, Siguencia F, Murakami K, Lee R, Sakatani T, Rosser CJ, <strong>Furuya H</strong>. Diagnostic accuracy of the Oncuria-Detect multiplex immunoassay in detecting upper tract urothelial carcinoma. <em>J Urol.</em> 2025 Nov 19. doi: 10.1097/JU.0000000000004803. Online ahead of print. PMID: 41042706. *Corresponding author</li>
    <li>Sakatani T, Tanaka S, Murakami K, Aguilar F, Chan OTM, Bresee C, Luthringer DJ, Rosser CJ, Hogrefe W, <strong>Furuya H</strong>. Development and analytical validation of a multiplex diagnostic qPCR-array as a potential application in predicting the response to neoadjuvant chemotherapy in muscle invasive bladder cancer. <em>Transl Oncol.</em> 2025 Sep 9;61:102528. doi: 10.1016/j.tranon.2025.102528. PMID: 40930009. *Corresponding author</li>
    <li>Tanaka S, Shimizu T, Pagano I, Hogrefe W, Dunbar S, Rosser CJ, <strong>Furuya H</strong>. Expanded performance comparison of the Oncuria 10-Plex bladder cancer urine assay using three different Luminex xMAP instruments. <em>Diagnostics (Basel).</em> 2025 Jul 10;15(14):1749. doi: 10.3390/diagnostics15141749. PMID: 40722499. <em>(Highlighted in a cover page)</em> *Corresponding author</li>
    <li>Siguencia F, Matsuda M, Pandyarajan V, Tanaka S, Smith SM, Seki E, Rosser CJ, <strong>Furuya H</strong>. Diagnostic performance of Liver FibraChek Dx, a blood-based test for the non-invasive detection of liver cirrhosis and cancer. <em>World J Hepatol.</em> 2025 Jun 27;17(6):106481. doi: 10.4254/wjh.v17.i6.106481. PMID: 40606917. *Corresponding author</li>
    <li>Pagano I, Zhang Z, Luu M, Tikhonenkov S, Le Calvez-Kelm F, Goodison S, Sakatani T, Murakami K, Kobayashi T, Avogbe P, Kim H, Lee R, Manel A, Vian E, Rosser CJ, <strong>Furuya H</strong>. Performance of the Oncuria-Detect bladder cancer test for evaluating patients presenting with haematuria: results from a real-world clinical setting. <em>J Transl Med.</em> 2025 Jun 18;23(1):680. doi: 10.1186/s12967-025-06749-z. PMID: 40533776. *Corresponding author</li>
    <li>Tanaka S, Murakami K, Sakatani T, Lee R, Hogrefe W, Siguencia F, Rosser CJ, <strong>Furuya H</strong>. Effects of different voided urine sample storage time, temperature, and preservatives on analysis with multiplex bead-based Oncuria bladder cancer immunoassay. <em>Diagnostics (Basel).</em> 2025 Jan 9;15(2):138. doi: 10.3390/diagnostics15020138. PMID: 39857022. *Corresponding author</li>
  </ol>

  <h3 style="margin-top:22px;">2024</h3>
  <ol class="small" style="line-height:1.6;">
    <li>Sagay AS, Hsieh SC, Dai YC, Chang CA, Ogwuche J, Ige OO, Kahansim ML, Chaplin B, Imade G, Elujoba M, Paul M, Hamel DJ, <strong>Furuya H</strong>, Khouri R, Boaventura VS, de Moraes L, Kanki PJ, Wang WK. Chikungunya virus antepartum transmission and abnormal infant outcomes in a cohort of pregnant women in Nigeria. <em>Int J Infect Dis.</em> 2024 Feb;139:92-100. doi: 10.1016/j.ijid.2023.11.036. Epub 2023 Dec 4. PMID: 38056689.</li>
    <li><strong>Furuya H</strong>, Sakatani T, Tanaka S, Murakami K, Waldron RT, Hogrefe W, Rosser CJ. Bladder cancer risk stratification with the Oncuria 10-plex bead-based urinalysis assay using three different Luminex xMAP instrumentation platforms. <em>J Transl Med.</em> 2024 Jan 2;22(1):8. doi: 10.1186/s12967-023-04811-2. PMID: 38167321. *Corresponding author</li>
  </ol>

  <h3 style="margin-top:22px;">2023</h3>
  <ol class="small" style="line-height:1.6;">
    <li>Qureshi TA, Chen X, Xie Y, Murakami K, Sakatani T, Kita Y, Kobayashi T, Miyake M, Knott SR, Li D, Rosser CJ, <strong>Furuya H</strong>. MRI/RNA-seq-based radiogenomics and artificial intelligence for more accurate staging of muscle-invasive bladder cancer. <em>Int J Mol Sci.</em> 2023 Dec 20;25(1):88. doi: 10.3390/ijms25010088. PMID: 38203254. *Corresponding author</li>
    <li>Murakami K^, <strong>Furuya H</strong>^*, Hokutan K, Goodison S, Pagano I, Chen R, Shen CH, Chan MWY, Ng CF, Kobayashi T, Ogawa O, Miyake M, Thornquist M, Shimizu Y, Hayashi K, Wang Z, Yu H, Rosser CJ. Association of SNPs in the PAI1 Gene with disease recurrence and clinical outcome in bladder cancer. <em>Int J Mol Sci.</em> 2023 Mar 3;24(5):4943. doi: 10.3390/ijms24054943. PMID: 36902377. ^co-first author, *Corresponding author</li>
  </ol>

  <h3 style="margin-top:22px;">2022</h3>
  <ol class="small" style="line-height:1.6;">
    <li>Chen R, Pagano I, Sun Y, Murakami K, Goodison S, Vairavan R, Tahsin M, Black PC, Rosser CJ, <strong>Furuya H</strong>. A diagnostic gene expression signature for bladder cancer can stratify cases into prescribed molecular subtypes and predict outcome. <em>Diagnostics (Basel).</em> 2022 Jul 25;12(8):1801. doi: 10.3390/diagnostics12081801. PMID: 35892512. *Corresponding author</li>
    <li><strong>Furuya H</strong>, Sasaki Y, Chen R, Peres R, Hokutan K, Murakami K, Kim N, Chan OTM, Pagano I, Dyrskjøt L, Jensen JB, Malmstrom PU, Segersten U, Sun Y, Arab A, Goodarzi H, Goodison S, Rosser CJ. PAI-1 is a potential transcriptional silencer that supports bladder cancer cell activity. <em>Sci Rep.</em> 2022 Jul 16;12(1):12186. doi: 10.1038/s41598-022-16518-3. PMID: 35842542. *Corresponding author</li>
    <li>Nikolos F, Hayashi K, Hoi XP, Alonzo ME, Mo Q, Kasabyan A, <strong>Furuya H</strong>, Trepel J, Di Vizio D, Guarnerio J, Theodorescu D, Rosser C, Apolo A, Galsky M, Chan KS. Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors. <em>Nat Commun.</em> 2022 Mar 28;13(1):1487. doi: 10.1038/s41467-022-29026-9. PMID: 35347124.</li>
    <li>Murakami K, Pagano I, <strong>Furuya H</strong>, Daskivich T, Mori D, Rosser CJ. Clinical utility of Oncuria™, a multiplexed liquid biopsy for the non-invasive detection of bladder cancer-a pilot study. <em>Diagnostics (Basel).</em> 2022 Jan 6;12(1):131. doi: 10.3390/diagnostics12010131. PMID: 35054300.</li>
    <li>Murakami K, Kamat AM, Dai Y, Pagano I, Chen R, Sun Y, Gupta A, Goodison S, Rosser CJ, <strong>Furuya H</strong>. Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: a pilot study. <em>Cancer Biomark.</em> 2022;33(1):151-157. doi: 10.3233/CBM-210221. PMID: 34511488. *Corresponding author</li>
  </ol>

  <h3 style="margin-top:22px;">2021</h3>
  <ol class="small" style="line-height:1.6;">
    <li>Hirasawa Y, Pagano I, Huang J, Sasaki Y, Murakami K, Rosser CJ, <strong>Furuya H</strong>. Case study of noni extract in men with very low-risk or low-risk prostate cancer. <em>Hawaii J Health Soc Welf.</em> 2021 Oct;80(10):242-250. PMID: 34661119. *Corresponding author</li>
    <li>Dorff T, Hirasawa Y, Acoba JD, Pagano I, Tamura DJ, Pal S, Zhang M, Waitz R, Dhal A, Haynes WA, Shon J, Scholz MC, <strong>Furuya H</strong>, Chan OTM, Huang J, Rosser CJ. Phase Ib study of patients with metastatic castrate resistant prostate cancer treated with different sequencing regimens of atezolizumab and Sipuleucel-T. <em>J Immunother Cancer.</em> 2021 Aug;9(8):e002931. doi: 10.1136/jitc-2021-002931. PMID: 34376554.</li>
    <li>Gouin KH, Ing N, Plummer JT, Rosser CJ, Cheikh BB, Oh C, Chen SS, Chan KS, <strong>Furuya H</strong>, Tourtellotte WG, Knott SRV, Theodorescu D. An N-Cadherin 2 expressing epithelial cell subpopulation predicts response to surgery, chemotherapy and immunotherapy in bladder cancer. <em>Nat Commun.</em> 2021 Aug 12;12(1):4906. doi: 10.1038/s41467-021-25103-7. PMID: 34385456.</li>
    <li>Murakami K, Pagano I, Chen R, Sun Y, Goodison S, Rosser CJ, <strong>Furuya H</strong>. Influencing factors on the Oncuria™ urinalysis assay: an experimental model. <em>Diagnostics (Basel).</em> 2021 Jun 3;11(6):1023. doi: 10.3390/diagnostics11061023. PMID: 34204951. *Corresponding author</li>
    <li>Hirasawa Y, Pagano I, Chen R, Sun Y, Dai Y, Gupta A, Tikhonenkov S, Goodison S, Rosser CJ, <strong>Furuya H</strong>. Diagnostic performance of Oncuria™, a urinalysis test for bladder cancer. <em>J Transl Med.</em> 2021 Apr 6;19(1):141. doi: 10.1186/s12967-021-02796-4. PMID: 33823873.</li>
  </ol>

  <h3 style="margin-top:22px;">2020</h3>
  <ol class="small" style="line-height:1.6;">
    <li><strong>Furuya H</strong>, Tabula L, Lee R, Kralovec P, Ramsden M, Wong R, Rosser CJ. Analytical validation of ONCURIA™ a multiplex bead-based immunoassay for the non-invasive bladder cancer detection. <em>Pract Lab Med.</em> 2020 Nov 13;22:e00189. doi: 10.1016/j.plabm.2020.e00189. PMID: 33294574.</li>
    <li><strong>Furuya H</strong>, Hayashi K, Shimizu Y, Kim N, Tsukikawa Y, Chen R, Sun Y, Chan OTM, Pagano I, Peres R, Hokutan K, Igari F, Chan KS, Rosser CJ. Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced bladder cancer mouse model. <em>J Transl Med.</em> 2020 Feb 5;18(1):57. doi: 10.1186/s12967-020-02239-6. PMID: 32024545.</li>
    <li>Itami Y, Miyake M, Ohnishi S, Tatsumi Y, Gotoh D, Hori S, Morizawa Y, Iida K, Ohnishi K, Nakai Y, Inoue T, Anai S, Tanaka N, Fujii T, Shimada K, <strong>Furuya H</strong>, Khadka VS, Deng Y, Fujimoto K. Disabled Homolog 2 (DAB2) protein in tumor microenvironment correlates with aggressive phenotype in human urothelial carcinoma of the bladder. <em>Diagnostics (Basel).</em> 2020 Jan 20;10(1):54. doi: 10.3390/diagnostics10010054. PMID: 31968685.</li>
    <li>Sukocheva OA, <strong>Furuya H</strong>, Ng ML, Friedemann M, Menschikowski M, Tarasov VV, Chubarev VN, Klochkov SG, Neganova ME, Mangoni AA, Aliev G, Bishayee A. Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target. <em>Pharmacol Ther.</em> 2020 Mar;207:107464. doi: 10.1016/j.pharmthera.2019.107464. PubMed PMID: 31863815. <em>(Review)</em></li>
  </ol>

  <h3 style="margin-top:22px;">2019</h3>
  <ol class="small" style="line-height:1.6;">
    <li><strong>Furuya H</strong>, Chan OTM, Hokutan K, Tsukikawa Y, Chee K, Kozai L, Chan KS, Dai Y, Wong RS, Rosser CJ. Prognostic significance of lymphocyte infiltration and a stromal immunostaining of a bladder cancer associated diagnostic panel in urothelial carcinoma. <em>Diagnostics (Basel).</em> 2019 Dec 28;10(1):14. doi: 10.3390/diagnostics10010014. PubMed PMID: 31905599.</li>
    <li><strong>Furuya H</strong>, Pagano I, Chee K, Kobayashi T, Wong RS, Lee R, Rosser CJ. Comparison of commercial ELISA kits, a prototype multiplex electrochemoluminescent assay, and a multiplex bead-based immunoassay for detecting a urine-based bladder-cancer-associated diagnostic signature. <em>Diagnostics (Basel).</em> 2019 Oct 29;9(4):166. doi: 10.3390/diagnostics9040166. PubMed PMID: 31671775.</li>
    <li>Huang J, Shiao SL, <strong>Furuya H</strong>, Rosser CJ. Immunogenomic analysis of exceptional responder to ALT-803 (IL-15 analogue) in BCG unresponsive nonmuscle invasive bladder cancer: a case series and review of the literature. <em>J Immunother.</em> 2019 Nov/Dec;42(9):354-358. doi: 10.1097/CJI.0000000000000269. PMID: 31107371.</li>
    <li>Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, Nakai Y, Inoue T, Anai S, Torimoto K, Tanaka N, Fujii T, <strong>Furuya H</strong>, Rosser CJ, Fujimoto K. Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: detection using prostatectomy and needle biopsy specimens. <em>Cells.</em> 2019 Mar 2;8(3):E212. doi: 10.3390/cells8030212. PMID: 30832347.</li>
    <li>Miyake M^, <strong>Furuya H</strong>^, Onishi S, Hokutan K, Anai S, Chan O, Shi S, Fujimoto K, Goodison S, Cai W, Rosser CJ. Monoclonal antibody against CXCL1 (HL2401) as a novel agent in suppressing IL6 expression and tumoral growth. <em>Theranostics.</em> 2019;9(3):853-867. doi: 10.7150/thno.29553. ^co-first author</li>
    <li><strong>Furuya H</strong>, Chan OTM, Pagano I, Zhu C, Kim N, Peres R, Hokutan K, Alter S, Rhode P, Rosser CJ. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model. <em>J Transl Med.</em> 2019 Jan 17;17(1):29. doi: 10.1186/s12967-019-1778-6. PMID: 30654801.</li>
    <li>Faiena I, Rosser CJ, Chamie K, <strong>Furuya H</strong>. Diagnostic biomarkers in non-muscle invasive bladder cancer. <em>World J Urol.</em> 2019 Oct;37(10):2009-2016. doi: 10.1007/s00345-018-2567-1. PMID: 30467596. *Corresponding author</li>
  </ol>

  <hr style="margin:22px 0; border:none; border-top:1px solid rgba(0,0,0,.12);" />

  <h3>Full list links</h3>
  <p class="small" style="line-height:1.7; margin:0;">
    <a href="https://www.ncbi.nlm.nih.gov/myncbi/hideki.furuya.1/bibliography/public/" target="_blank" rel="noopener">PubMed bibliography</a><br>
    <a href="https://scholar.google.com/citations?user=yriwzHAAAAAJ&hl=en" target="_blank" rel="noopener">Google Scholar</a>
  </p>

</div>
